Table 2.

Subgroup analyses of somatostatin analogues effects on liver volume as compared to placebo/standard management.

Subgroup	Unstandardized mean difference (95% CI)	P
Sample size		0.951
< 50	− 171 (− 458, 112)
≥ 50	− 186 (− 580, 208)
Follow-up		0.694
≤ 1 year	− 130 (− 454, 194)
> 1 year	− 222 (− 548, 103)
Female Gender		0.555
< 50%	− 85 (− 465, 295)
≥ 50%	− 229 (− 517, 60)
Baseline eGFR		0.512
< 60 ml/min	− 111 (− 412, 190)
≥ 60 ml/min	− 267 (− 622, 89)
Study drug		0.855
Octreotide LAR/Lanreotide	− 170 (− 409, 69)
Pasireotide	− 249 (− 1066, 568)
Liver volume evaluation		0.589
CT	− 99 (− 459, 259)
MRI	− 228 (− 527, 70)
Baseline liver volume		0.920
< 2000 ml	− 167 (− 453, 118)
≥ 2000 ml	− 192 (− 578, 194)
Presence of patients with isolated PLD		0.799
Yes	− 251 (− 874, 371)
No	− 164 (− 411, 83)

eGFR estimated glomerular filtration rate, CI confidence interval, CT computed tomography, MRI magnetic resonance imaging, PLD polycystic liver disease.